🇺🇸 FDA
Pipeline program

Vyvgart 1 000 mg solution for injection

ARGX-113-2207

Phase 3 small_molecule active

Quick answer

Vyvgart 1 000 mg solution for injection for Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
Argenx
Indication
Generalized Myasthenia Gravis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials